伴高乳酸血症的重症患者行局部CRA-CRRT治疗的有效性和安全性研究Study on efficacy and safety of local citric acid anticoagulation and continuous renal replacement therapy (CRA-CRRT) therapy in severe patients with hyperlactatemia
杜国伦,李超,张红丽
摘要(Abstract):
目的 研究伴高乳酸血症的重症患者行局部枸橼酸抗凝(CRA)-连续性肾脏替代(CRRT)治疗的有效性和安全性。方法 收集2021年10月-2023年3月于新疆医科大学第一附属医院呼吸重症监护室进行RCA-CRRT治疗的67例伴高乳酸血症(2 mmol/L<乳酸值<10 mmol/L)的重症患者临床资料,按局部抗凝方式分为对照组(低分子肝素抗凝)20例和CRA组(枸橼酸抗凝)47例。收集患者一般资料及CRRT治疗前及治疗24 h患者乳酸值、pH值、碳酸氢根离子(HCO~-_3)、滤器后血清离子钙(iCa~(2+))、体内iCa~(2+)、血清总钙、血钠离子(Na~+)、镁离子(Mg~(2+));统计滤器结局、血液制品输注情况、出血事件发生率及死亡率,记录CRA相关并发症发生情况。结果 两组一般资料比较,差异均无统计学意义(P>0.05);与本组治疗前比较,CRRT治疗24 h两组乳酸值水平均降低,iCa~(2+)、pH、HCO_3~-水平升高(P<0.05);CRRT治疗24 h后,两组患者总钙、总钙/iCa~(2+)比值、Na~+、Mg~(2+)水平比较,差异均无统计学意义(P>0.05)。与对照组比较,CRA组滤器平均使用寿命延长,差异有统计学意义(P<0.05),两组治疗期间出血事件发生率、血液制品输注情况、死亡率差异均无统计学意义(P>0.05);两组患者治疗24 h滤器或管路凝血发生率等级分布比较,差异有统计学意义(P<0.05),且CRA组Ⅱ/Ⅲ级凝血发生率低于对照组(P<0.05);两组患者枸橼酸蓄积、代谢性酸中毒、代谢性碱中毒发生率及总并发症发生率比较,差异无统计学意义(P>0.05)。结论 伴高乳酸血症的重症患者行CRA-CRRT治疗有助于降低血乳酸水平,纠正酸中毒,减少凝血和出血风险,延长滤器寿命,枸橼酸蓄积风险低。
关键词(KeyWords): 连续性肾脏替代治疗;局部枸橼酸抗凝;高乳酸血症;有效性;安全性
基金项目(Foundation): 新疆维吾尔自治区自然科学基金项目(2020D01E253)
作者(Author): 杜国伦,李超,张红丽
参考文献(References):
- [1] HOFF B M,MAKER J H,DAGER W E,et al.Antibiotic dosing for critically ill adult patients receiving intermittent hemodialysis,prolonged intermittent renal replacement therapy,and continuous renal replacement therapy:An update[J].Ann Pharmacother,2020,54(1):43-55.
- [2] TANDUKAR S,KIM C,KALRA K,et al.Severe hyponatremia and continuous renal replacement therapy:Safety and effectiveness of low-sodium dialysate[J].Kidney Med,2020,2(4):437-449.
- [3] QI W,LIU J,LI A.Regional citrate anticoagulation or heparin anticoagulation for renal replacement therapy in patients with liver failure:A systematic review and meta-analysis[J].Clin Appl Thromb Hemost,2023,29(36):107-117.
- [4] SHARROCK L,ANKRAVS M J,DEANE A M,et al.Clearance of piperacillin-tazobactam and vancomycin during continuous renal replacement with regional citrate anticoagulation[J].Ther Drug Monit,2023,45(2):265-268.
- [5] VERHAEGHE M,HACHIMI-IDRISSI S.Blood lactate and lactatekineticsas treatment and prognosis markers for tissuehypoperfusion [J].Acta Clin Belg,2020,75(1):1-8.
- [6] KHADZHYNOV D,DAHLINGER A,SCHELTER C,et al.Hyperlactatemia,lactatekinetics and prediction of citrate accumulation incritically patientsundergoing continuousrenal replacementtherapy with regional citrate anticoagulation[J].Crit Care Med,2017,45(9):941- 940.
- [7] TAN J N,HAROON S,MUKHOPADHYAY A,et al.Hyperlactatemiapredicts citrate intolerance with regional citrateanticoagulationduring continuous renal replacement therapy [J].Intensive Care Med,2019,34(5):418- 425.
- [8] BAGSHAW S M,CHAKRAVARTHI M R,ADQI CONSENSUS GROUP,et al.Precision continuous renal replacementtherapy and solute control [J].Blood Purif,2016,42(3):238-247.
- [9] 中华医学会肾脏病学分会专家组.连续性肾脏替代治疗的抗凝管理指南[J].中华肾脏病杂志,2022,38(11):1016-1024.
- [10] 陈文健,赵娟娟.探讨下腔静脉滤器植入联合导管溶栓治疗下肢深静脉血栓形成的临床疗效[J].医药卫生杂志,2022,16(2):4-8.
- [11] 中华医学会肾脏病学分会专家组.连续性肾脏替代治疗的抗凝管理指南[J].中华肾脏病杂志,2022,38(11):1016-1024.
- [12] 王婷,张燕,李保华.连续性肾脏替代治疗对重症肺炎所致急性肾损伤患者TLR2和TLR4的影响[J].新疆医科大学学报,2017,40(2):1-3.
- [13] MARIANO F,TEDESCHI L,MORSELU M,et al.Normal ci-tratemia and metabolic tolerance of citrate anticoagulation for he-modiafiltration in severe septicshock bum patients[J].Inten-sive Care Med,2010,36(10):1735-1743.
- [14] 吴树彬,李春华,任宪凤,等.Stewart-Fencl血气判断方法对危重症患者代谢性酸碱失衡的诊断价值[J].中日友好医院学报,2021,35(3):5-7.
- [15] 班文彦,韩舒,付贺飞,等.超声心动图提示线粒体脑肌病伴高乳酸血症和脑卒中样发作综合征早期心肌受损2例[J].中国医学影像技术杂志,2022,38(2):2-5.
- [16] 田丽,王建刚,刘新宇.枸橼酸抗凝在乳酸酸中毒患者连续性肾脏替代治疗中的应用价值[J].临床肾脏病杂志,2019,19(3):5-8.
- [17] 张琪,丁峰.连续性肾脏替代治疗中局部枸橼酸抗凝的临床监测及风险评估[J].华西医学杂志,2022,37(7):6-9.
- [18] CHONG G,JEE-YOUN G,PARK N,et al.Intratu-moral budding :A novel prognostic biomarker for tumor recur-rence and a potential predictor of nodalmetastasis in uterine cer-vicalcancer[J].Enr Surg Oncol,2021,47(12):3182-3187.